Lifeward names Keith D. Rose as Chief Medical Officer
Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026. He has served in several senior medical affairs roles at the company since March 2023, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences.
Before joining Lifeward, Dr. Rose held medical leadership positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior. He earned his medical degree with distinction from The George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
CMO effective date: May 1, 2026
Announcement date: May 18, 2026
Residency duration: Five-year residency
3 metrics
CMO effective date
May 1, 2026
Effective date of Keith D. Rose, M.D. as Chief Medical Officer
Announcement date
May 18, 2026
Date Lifeward announced the CMO appointment
Residency duration
Five-year residency
Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine
Key Terms
Chief Medical Officer, Emerging growth company, Medical Affairs, Neurosciences
4 terms
Chief Medical Officer financial
"announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer of the Company"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Medical Affairs technical
"National Medical Director, Medical Affairs – Neurosciences and Medical Director, Consultant, Medical Affairs – Neurosciences"
Medical affairs is the team in a healthcare company that translates clinical science into clear, accurate information for doctors, regulators and patients, and manages post-approval safety and education. Think of it as a trusted translator and guide that helps ensure a drug or device is used correctly, understood by the medical community, and monitored after launch — factors that affect regulatory outcomes, adoption and long-term commercial value for investors.
Neurosciences technical
"National Medical Director, Medical Affairs – Neurosciences and Medical Director, Consultant, Medical Affairs – Neurosciences"
The neurosciences are the collection of scientific and medical fields that study the brain, spinal cord and nerves to understand how they produce thoughts, sensations and movement. For investors, breakthroughs or setbacks in this area affect the value of companies developing drugs, devices or tests for neurological conditions because progress can mean large markets, long development timelines, high regulatory risk and potentially lasting competitive advantage—think of it as engineering solutions for the body’s most complex computer.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive change did Lifeward (LFWD) announce on May 18, 2026?
Lifeward announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026. He previously held senior medical affairs roles at Lifeward since March 2023 and brings extensive clinical and industry experience in neurosciences and medical affairs leadership.
What is Keith D. Rose, M.D.’s background before becoming Lifeward (LFWD) Chief Medical Officer?
Before becoming Chief Medical Officer, Dr. Rose served as Vice President, Medical Affairs, Medical Director – Neurosciences at Lifeward. Earlier roles included senior medical affairs and clinical positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior, providing broad experience across multiple therapeutic areas.
When did Keith D. Rose, M.D. officially assume the Chief Medical Officer role at Lifeward (LFWD)?
Keith D. Rose, M.D. officially assumed the Chief Medical Officer role effective May 1, 2026. The company disclosed the appointment on May 18, 2026, highlighting his prior internal leadership roles in medical affairs and his broader pharmaceutical and clinical research experience.
What are some of Keith D. Rose, M.D.’s prior positions within Lifeward (LFWD)?
Within Lifeward, Dr. Rose previously served as National Medical Director, Medical Affairs – Neurosciences, Medical Director, Consultant, Medical Affairs – Neurosciences, and most recently Vice President, Medical Affairs, Medical Director – Neurosciences, demonstrating a progression of responsibilities in the company’s medical leadership.
What education and training does Lifeward (LFWD) Chief Medical Officer Keith D. Rose, M.D. have?
Dr. Rose earned his Doctor of Medicine degree with distinction from The George Washington University School of Medicine. He completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine, giving him combined expertise in rehabilitation and pediatric care.
Which other companies did Lifeward (LFWD) CMO Keith D. Rose, M.D. work for previously?
Before Lifeward, Dr. Rose worked at Biocodex, Inc. as Medical Director, Medical Affairs and at Novocure, Inc. as Lead Clinical Research Scientist/Regional Manager in Oncology. He also held senior medical affairs and clinical leadership roles at Ipsen, Jazz Pharmaceuticals and Indivior.
AI-generated analysis. How Rhea-AI works. Not financial advice.
